The effect of sulfasalazine and its active components on human polymorphonuclear leukocyte function in relation to ulcerative colitis
- PMID: 43662
- DOI: 10.1111/j.0954-6820.1979.tb13545.x
The effect of sulfasalazine and its active components on human polymorphonuclear leukocyte function in relation to ulcerative colitis
Abstract
Sulfasalazine and its active components, 5-aminosalicylic acid (5-ASA) and sulfapyridine (SP), are potent modulators of inflammatory reactions but with somewhat different modes of action. Investigating the effect of these compounds on normal human polymorphonuclear leukocytes in vitro, we show inhibition of different stages in the phagocytic process, such as migration (sulfasalazine and SP), superoxide production (sulfasalazine and SP), myeloperoxidase-mediated iodination and cytotoxicity (5-ASA and SP). It is thus suggested that sulfasalazine is not just a vehicle for delivering its active components in the colon, but that its therapeutic effect is ulcerative colitis and other inflammatory reactions is a result of the concurrent action of the three compounds.
Similar articles
-
Inhibition of leucocyte motility by drugs used in ulcerative colitis.Gut. 1981 Aug;22(8):642-7. doi: 10.1136/gut.22.8.642. Gut. 1981. PMID: 6116649 Free PMC article.
-
Effects of BX661A, a new therapeutic agent for ulcerative colitis, on chemotaxis and reactive oxygen species production in polymorphonuclear leukocytes in comparison with salazosulfapyridine and its metabolite sulfapyridine.Arzneimittelforschung. 1998 Dec;48(12):1163-7. Arzneimittelforschung. 1998. PMID: 9893931
-
Sulfasalazine and its metabolites attenuate respiratory burst of leukocytes--a possible mechanism of anti-inflammatory effects.J Clin Lab Immunol. 1987 May;23(1):31-3. J Clin Lab Immunol. 1987. PMID: 2886669
-
[Pharmacological bases of therapy with 5-ASA].Gastroenterol Hepatol. 1997 Jun-Jul;20(6):322-34. Gastroenterol Hepatol. 1997. PMID: 9296850 Review. Spanish. No abstract available.
-
The short- and long-term safety of 5-aminosalicylate products in the treatment of ulcerative colitis.Rev Gastroenterol Disord. 2004 Spring;4(2):86-91. Rev Gastroenterol Disord. 2004. PMID: 15185719 Review.
Cited by
-
Inhibition of leucocyte motility by drugs used in ulcerative colitis.Gut. 1981 Aug;22(8):642-7. doi: 10.1136/gut.22.8.642. Gut. 1981. PMID: 6116649 Free PMC article.
-
Which component of sulphasalazine is active in rheumatoid arthritis?Br Med J (Clin Res Ed). 1985 Jul 13;291(6488):138. doi: 10.1136/bmj.291.6488.138. Br Med J (Clin Res Ed). 1985. PMID: 2861878 Free PMC article. No abstract available.
-
Effect of sulphasalazine and sulphapyridine on neutrophil superoxide production: role of cytosolic free calcium.Ann Rheum Dis. 1990 May;49(5):296-300. doi: 10.1136/ard.49.5.296. Ann Rheum Dis. 1990. PMID: 1971506 Free PMC article.
-
Possible mode of action of 5-aminosalicylic acid.Dig Dis Sci. 1987 Dec;32(12 Suppl):51S-56S. doi: 10.1007/BF01312464. Dig Dis Sci. 1987. PMID: 2891468
-
Immunosuppressive drugs in inflammatory bowel disease. A review of their mechanisms of efficacy and place in therapy.Drugs. 1989 Aug;38(2):267-88. doi: 10.2165/00003495-198938020-00007. Drugs. 1989. PMID: 2670519 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials